{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:29:32Z","timestamp":1790368172814,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jjcc.2022.04.003","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T09:10:50Z","timestamp":1652346650000},"page":"432-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Outcome of mean pulmonary arterial pressure-based intensive treatment for patients with pulmonary arterial hypertension"],"prefix":"10.1016","volume":"80","author":[{"given":"Yoichi","family":"Sugiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Shimokawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2022.04.003_bb0005","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"The 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0010","doi-asserted-by":"crossref","first-page":"1801889","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0015","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1183\/09031936.00078411","article-title":"ASPIRE registry: assessing the spectrum of pulmonary hypertension identified at a REferral centre","volume":"39","author":"Hurdman","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0020","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","article-title":"Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era","volume":"122","author":"Humbert","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1253\/circj.CJ-17-0139","article-title":"Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese patients with pulmonary arterial hypertension","volume":"82","author":"Tamura","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1378\/chest.81.2.151","article-title":"Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data","volume":"81","author":"Riedel","year":"1982","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0035","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1378\/chest.119.3.818","article-title":"Prognostic factors in medically treated patients with chronic pulmonary embolism","volume":"119","author":"Lewczuk","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0045","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0050","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.lfs.2014.01.077","article-title":"Long-term patient survival with idiopathic\/heritable pulmonary arterial hypertension treated at a single center in Japan","volume":"118","author":"Ogawa","year":"2014","journal-title":"Life Sci"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0055","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.amjcard.2017.01.015","article-title":"Survival of Japanese patients with idiopathic\/heritable pulmonary arterial hypertension","volume":"119","author":"Ogawa","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0060","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1253\/circj.CJ-66-0158","article-title":"Guidelines for the treatment of pulmonary hypertension (JCS 2017\/JPCPHS 2017)","volume":"83","author":"Fukuda","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0065","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","article-title":"A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension","volume":"39","author":"Kylhammar","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0070","doi-asserted-by":"crossref","first-page":"1700740","DOI":"10.1183\/13993003.00740-2017","article-title":"Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0075","doi-asserted-by":"crossref","first-page":"1700889","DOI":"10.1183\/13993003.00889-2017","article-title":"Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0080","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies","volume":"156","author":"Benza","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0090","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0095","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1183\/09031936.00116313","article-title":"Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study","volume":"43","author":"Sitbon","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0100","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201507-1398OC","article-title":"Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension","volume":"192","author":"Hassoun","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"ehz746.0031","key":"10.1016\/j.jjcc.2022.04.003_bb0105","article-title":"Upfront triple combination therapy with ambrisentan, tadalafil and subcutaneous treprostinil in incident patients with severe pulmonary arterial hypertension","volume":"40","author":"D\u2019Alto","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0110","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1183\/13993003.02043-2015","article-title":"Initial dual oral combination therapy in pulmonary arterial hypertension","volume":"47","author":"Sitbon","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jjcc.2018.02.009","article-title":"Clinical prediction score for identifying patients with pulmonary veno-occlusive disease\/pulmonary capillary hemangiomatosis","volume":"72","author":"Ogawa","year":"2018","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0120","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1183\/09031936.00090608","article-title":"Pulmonary veno-occlusive disease","volume":"33","author":"Montani","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0125","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.10-0969","article-title":"Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study","volume":"140","author":"Rubin","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0130","doi-asserted-by":"crossref","first-page":"2000041","DOI":"10.1183\/13993003.00041-2020","article-title":"Mild parenchymal lung disease and\/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension","volume":"55","author":"Lewis","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jjcc.2022.04.003_bb0135","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2019-216274","article-title":"Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis","volume":"79","author":"Kuwana","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508722000910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508722000910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:08:22Z","timestamp":1760274502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508722000910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0914508722000910"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2022.04.003","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of mean pulmonary arterial pressure-based intensive treatment for patients with pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2022.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}